Vnitr Lek 2016, 62(Suppl 3):17-21

The course of differentiated thyroid microcarcinoma in patients treated by different therapeutic strategies

Marianna Grigerová1,2,*, Martin Griger3, Emília Mojtová1,2, Ján Podoba1,2
1 Klinika endokrinológie LF SZU, Bratislava, Slovenská republika
2 Onkologický ústav svätej Alžbety, s.r.o, Bratislava, Slovenská republika
3 EuroPainClinics Bratislava, Slovenská republika

Low risk differentiated thyroid microcarcinoma therapy is a controversial area of thyroid tumor management. Major international medical societies and reputable institutes consider lobectomy to be sufficient therapeutic intervention for the pT1a cN0cM0 stage of papillary thyroid microcarcinoma. However different views and therapeutic strategies exist and result in unnecessary overtreatment and worsening of patient's quality of life. We researched the course of the differentiated thyroid microcarcinoma in patients using different therapeutic strategies: lobectomy, total thyroidectomy, total thyroidectomy with central compartment prophylactic lymphadenectomy and total thyroidectomy followed by radioactive iodine treatment. Apart from an excellent prognosis we did not find out any clinically significant differences in the course of the disease. We can conclude that lobectomy is sufficient therapeutic intervention for patients with differentiated thyroid microcarcinoma without known metastases.

Keywords: differentiated thyroid microcarcinoma; management; overtreatment; the course of the disease

Received: August 30, 2016; Accepted: September 15, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grigerová M, Griger M, Mojtová E, Podoba J. The course of differentiated thyroid microcarcinoma in patients treated by different therapeutic strategies. Vnitr Lek. 2016;62(Supplementum 3):17-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baudin E, Travagli JP, Ropers J et al. Microcarcinoma of the thyroid gland. Cancer 1998; 83(3): 553-559. Go to original source...
    2. Lee J, Rhee Y, Lee S et al. Frequent, Aggressive Behaviors of Thyroid Microcarcinomas in Korean Patients. Endocr J 2006; 53(5): 627-632. Go to original source... Go to PubMed...
    3. Rodriguez JM, Moreno A, Parrilla P et al. Papillary thyroid microcarcinoma: clinical study and prognosis. Eur J Surg. 1997; 163(4): 255-259. Go to PubMed...
    4. Pacini F, Schlumberger M, Dralle H et al. [European Thyroid Cancer Taskforce]. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154(6): 787-803. Erratum in Eur J Endocrinol 2006; 155(2): 385. Go to original source... Go to PubMed...
    5. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1-133. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0020>. Go to original source... Go to PubMed...
    6. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17(8): 873-890. Erratum in Stat Med 1999; 18(10): 1293. Go to original source... Go to PubMed...
    7. Sugitani I, Toda K, Yamada K et al. Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes. World J Surg 2010; 34(6): 1222-1231. Go to original source... Go to PubMed...
    8. Ito Y, Miyauchi A, Kihara M et al. Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation. Thyroid 2014; 24(1): 27-34. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2013.0367>. Go to original source... Go to PubMed...
    9. Oda H, Miyauchi A, Ito Y et al. Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 2016; 26(1): 150-155. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0313>. Go to original source... Go to PubMed...
    10. Takami H, Ito Y, Okamoto T et al. Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg 2010; 35(1): 111-121. Dostupné z DOI: <http://dx.doi.org/10.1007/s00268-010-0832-6>. Go to original source... Go to PubMed...
    11. Wada N, Duh QY, Sugino K et al. Lymph Node Metastasis From 259 Papillary Thyroid Microcarcinomas: Frequency, Pattern of Occurrence and Recurrence, and Optimal Strategy for Neck Dissection. Ann Surg 2003; 237(3): 399-407. Go to original source... Go to PubMed...
    12. Ito Y, Kudo T, Kobayashi K et al. Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5,768 Patients with Average 10-year Follow-up. World J Surg 2012; 36(6): 1274-1278. Dostupné z DOI: <http://dx.doi.org/10.1007/s00268-012-1423-5>. Go to original source... Go to PubMed...
    13. Chen Y, Sadow PM, Suh H et al. BRAFV600E Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid 2016; 26(2): 248-255. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0391>. Go to original source... Go to PubMed...
    14. Pyo JS, Sohn JH, Kng G. Detection of Tumor Multifocality Is Important for Prediction of Tumor Recurrence in Papillary Thyroid Microcarcinoma: A Retrospective Study and Meta-Analysis. J Pathol Transl Med 2016; 50(4): 278-286. Dostupné z DOI: <http://dx.doi.org/10.4132/jptm.2016.03.29>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.